ArticleJournal of clinical medicine2022
Oxygen-Ozone Therapy in Cervicobrachial Pain: A Real-Life Experience.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 9 citations in OpenAlex.
- Efficacy of Oxygen-Ozone Therapy for Shoulder Disorders: A Systematic Review of Randomized Controlled Trials.Journal of clinical medicine · 2026Review
- Effects of Oxygen-Ozone Therapy and Physiotherapy on Functioning in Patients with Chronic Non-Specific Neck Pain: A Prospective Double-Arm Pilot Study.Journal of functional morphology and kinesiology · 2026Article
- Emerging ozone generation strategies: mechanistic insights and application-driven developments.RSC advances · 2026Review
- Medical ozone: mechanisms, biological effects and clinical evidence-a narrative review.Frontiers in medicine · 2026Review
- How Safe Are Oxygen-Ozone Therapy Procedures for Spine Disc Herniation? The SIOOT Protocols for Treating Spine Disorders.Journal of imaging · 2025Article
- Effects of Ozone Therapy on Adverse Events and Inflammatory Markers in Patients With Hepatocellular Carcinoma Undergoing Interventional Therapy.Gastroenterology research and practice · 2025Article
- Assessing Gender Differences in Neuropathic Pain Management: Findings from a Real-Life Clinical Cross-Sectional Observational Study.Journal of clinical medicine · 2024Article
- Ozone therapy in musculoskeletal medicine: a comprehensive review.European journal of medical research · 2024Review
- Oxygen-Ozone Therapy of Musculoskeletal Neck Pain: A Review.Journal of personalized medicine · 2024Review
- A Multiple Synergic Treatment for Non-Healing Ulcer Management in a Patient withReports (MDPI) · 2023Article
- Ozone in Chemotherapy-Induced Peripheral Neuropathy-Current State of Art, Possibilities, and Perspectives.International journal of molecular sciences · 2023Review
- Mitochondrial dysfunction/hyperfunction inducing excessive mtROS in inflammatory and neuropathic pain.Molecular painReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This prospective, open-label clinical study was carried out to evaluate both the efficacy and safety of intramuscular paravertebral injections of an oxygen−ozone (O2−O3) mixture in patients with cervicobrachial pain. We enrolled 540 subjects affected by cervicobrachial pain referred to the Ozone Therapy Ambulatory at the Mater Domini Hospital of Catanzaro (Italy) and to the Center of Pain in Taurianova (Reggio Calabria, Italy). All the subjects (n = 540) completed the treatment and the follow-up visits. The subjects received a mean of 11 cervical intramuscular treatments with an O2−O3 mixture (5 mL) with an O3 concentration of 10 μg/mL bis a week. The improvement of pain was measured by a change in the mean of the Visual Analog Scale (VAS) score from baseline to the end of treatment and during follow-ups. Patient satisfaction was assessed at the end of treatment using the SF-36 Questionnaire. The development of adverse drug reactions was recorded. The mean (±standard deviation) VAS pain score at baseline, at the end of treatment, and during follow-ups showed a significant reduction in pain over time (p < 0.001). All the patients who were enrolled (n: 540) were pain-free after one year. According to the pain distribution, all subjects showed a significant reduction in pain over time in each group (p < 0.05). No significant differences were observed with respect to sex or age. No adverse events were observed during the study. In conclusion, we documented that the intramuscular injection of an O2−O3 mixture is an effective and safe treatment option for patients with cervicobrachial pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.